WO2016053121A1 - Formulation pharmaceutique antivirale pour le traitement de la fièvre dengue, du virus de la grippe et du vih/sida - Google Patents

Formulation pharmaceutique antivirale pour le traitement de la fièvre dengue, du virus de la grippe et du vih/sida Download PDF

Info

Publication number
WO2016053121A1
WO2016053121A1 PCT/PH2015/000015 PH2015000015W WO2016053121A1 WO 2016053121 A1 WO2016053121 A1 WO 2016053121A1 PH 2015000015 W PH2015000015 W PH 2015000015W WO 2016053121 A1 WO2016053121 A1 WO 2016053121A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
dengue
sodium phosphate
procaine
dexamethasone
Prior art date
Application number
PCT/PH2015/000015
Other languages
English (en)
Inventor
Ruben Garcia FABUNAN
Original Assignee
Fabunan Ruben Garcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabunan Ruben Garcia filed Critical Fabunan Ruben Garcia
Publication of WO2016053121A1 publication Critical patent/WO2016053121A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Influenza or better known as the flu is a highly contagious illness that can occur in children or adults of any age more often in the winter months as it is easily spread from person-to-person by coughing, sneezing, or touching surfaces. Every year, the United States alone have more than 200,000 people that are hospitalized due to complications of the flu. On some instances, flu outbreaks also occur in many parts of the world when new strains of influenza viruses formed.
  • the antidote comprises effective amounts of procaine hydrochloride with epinephrine and dexamethasone sodium phosphate, preferably present from about 5 to about 20 milligrams of procaine per milliliter, 2% with epinephrine, and from about 4 to 8 milligrams of dexamethasone sodium phosphate per milliliter. Still, the present inventor, through US 6,172,053 (herein referred to as
  • USPN ⁇ 53 has initially provided treatment for a broad spectrum of diseases for which dengue, influenza and HIV/AIDS are included.
  • USPN ⁇ 53 broadly disclosed a method of treatment for human individuals infected with Dengue fever virus, influenza virus or HIV/AIDS virus comprising administering to said individuals, a liquid mixture of procaine hydrochloride in the range of 5 to 40 mg and dexamethasone sodium phosphate in the range of 1 to 4 mg., that is compounded manually right or just before the administration by mixing a prescribed amount of an US FDA (Food and Drugs Administration)-approved aqueous solution of procaine hydrochloride with a prescribed amount of an US FDA-approved aqueous solution of dexamethasone sodium phosphate.
  • FDA Food and Drugs Administration
  • this invention provides an injectable preparation comprising the pharmaceutical composition of definite range of procaine and dexamethasone.
  • the present invention also provides methods for the treatment of human virus diseases in an individual infected with Dengue fever virus, influenza virus and HIV/AIDS comprising administering to said individual in need thereof an effective amount of an antiviral formulation comprising the combination of procaine and dexamethasone.
  • the present invention relates to a specific formulation comprising 7 to 11 parts procaine hydrochloride in combination with 1 part dexamethasone sodium phosphate or the ratio of procaine hydrochloride to dexamethasone sodium phosphate is 7:1 to 11 : 1 , preferably 9:1 , for HIV treatment.
  • the pharmaceutical formulation comprises 4 parts procaine hydrochloride with 1 part dexamethasone sodium phosphate or the ratio of procaine hydrochloride to dexamethasone sodium phosphate is 4:1.
  • the specific formulations of the present invention provide optimal effect compared with the formulations disclosed and taught in USPN ⁇ 53.
  • DHF Dengue Hemorrhagic Fever
  • DFS Dengue Shock Syndrome
  • the interval between the 2 injections per day should be at least 1 and / 2 to 2 hours apart or longer.
  • the interval between the 2 injections per day should be at least 1 and 1 ⁇ 2 to 2 hours apart or longer.
  • One skilled in the art would readily determine the total mg of each of the procaine hydrochloride and dexamethasone sodium phosphate that is utilized for the described 2ml, 1.5 ml or 1 ml combined formulations.
  • Sub-optimal ratio 12 to 1 (Procaine to Dexamethasone), 2 times per day, with a Duration of Treatment of 6 days - minimal improvement of condition
  • Optimum ratio 4 to 1 (Procaine to Dexamethasone), 2 times per day, with a Duration of Treatment of 5 days will lead to full recovery.
  • the synergistic effect of the combination of the two drugs is most effective at this ratio and this duration of treatment is found to be the optimal treatment for full recovery.
  • Sub-optimal ratio 12 to 1 (Procaine to Dexamethasone), 2 times per day, with a Duration of Treatment of 6 days - minimal improvement of condition B)
  • Sub-optimal ratio 12 to 1 (Procaine to Dexamethasone), 2 times per day, with a Duration of Treatment of 6 days - minimal improvement of condition B)
  • Sub-optimal ratio 1 to 1 (Procaine to Dexamethasone), 2 times per day, with a Duration of Treatment for 2 days - never reached full recovery and minimal improvement of condition
  • Sub-optimal ratio 12 to 1 (Procaine to Dexamethasone), 2 times per day, with a Duration of Treatment of 6 months - improvement of condition but not full recovery
  • Ratio is 4 to 1 Procaine Hydrochloride to
  • Total for one dose or one injection 1.5 ml for adults and 1 ml for children 12 years old or younger.
  • Total for one dose or one injection 1.5 ml for adults and 1 ml for children 12 years old or younger.
  • Ratio is 9 to 1 Procaine Hydrochloride to dexamethasone Sodium Phosphate

Abstract

La présente invention concerne une formulation pharmaceutique améliorée pour le traitement de maladies virales, en particulier pour le traitement de la fièvre dengue, du virus de la grippe et du VIH/SIDA. La formulation comprend de la procaïne et de la dexaméthasone dans des proportions spécifiques pour la récupération complète et rapide de patients souffrant de la fièvre dengue classique, de la fièvre dengue hémorragique (DHF) & et de la dengue avec syndrome de choc (DSS), de la grippe virale, et du VIH/SIDA.
PCT/PH2015/000015 2014-09-30 2015-09-30 Formulation pharmaceutique antivirale pour le traitement de la fièvre dengue, du virus de la grippe et du vih/sida WO2016053121A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PH1/2014/000275 2014-09-30
PH12014000275A PH12014000275A1 (en) 2014-09-30 2014-09-30 Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids

Publications (1)

Publication Number Publication Date
WO2016053121A1 true WO2016053121A1 (fr) 2016-04-07

Family

ID=54337324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PH2015/000015 WO2016053121A1 (fr) 2014-09-30 2015-09-30 Formulation pharmaceutique antivirale pour le traitement de la fièvre dengue, du virus de la grippe et du vih/sida

Country Status (2)

Country Link
PH (1) PH12014000275A1 (fr)
WO (1) WO2016053121A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU101724B1 (de) * 2020-04-02 2021-10-04 Inflamed Pharma Gmbh Wirkstoffe zur medizinischen Verwendung
WO2021198504A1 (fr) * 2020-04-02 2021-10-07 Inflamed Pharma Gmbh Principes actifs à usage médical
CN115697318A (zh) * 2020-04-02 2023-02-03 炎症药物有限责任公司 医用活性物质

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492901A (en) * 1994-08-16 1996-02-20 Fabunan; Ruben G. Cobranin-F injection envenomation antidote
PH31161A (en) 1996-05-23 1998-03-20 Ruben G Pabunan Crobranin-f injection envenomation antidote.
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US6172053B1 (en) 1999-02-24 2001-01-09 Ruben G. Fabunan Injection viral treatment
WO2007084548A2 (fr) * 2006-01-18 2007-07-26 Fil-Am Tech., Inc. Traitement viral
WO2007100525A2 (fr) * 2006-02-27 2007-09-07 Fil-Am Tech., Inc. Traitement antiviral

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5492901A (en) * 1994-08-16 1996-02-20 Fabunan; Ruben G. Cobranin-F injection envenomation antidote
PH31161A (en) 1996-05-23 1998-03-20 Ruben G Pabunan Crobranin-f injection envenomation antidote.
US6172053B1 (en) 1999-02-24 2001-01-09 Ruben G. Fabunan Injection viral treatment
WO2007084548A2 (fr) * 2006-01-18 2007-07-26 Fil-Am Tech., Inc. Traitement viral
WO2007100525A2 (fr) * 2006-02-27 2007-09-07 Fil-Am Tech., Inc. Traitement antiviral

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELBOURAKADI, NAJOUA: "A Novel Method For The Selective Elimination Of HIV Infected Cells: Dexamethasone And Procaine As A Combination TherapyPrototype", 2011, XP002750987, Retrieved from the Internet <URL:https://libres.uncg.edu/ir/uncg/f/Elbourakadi_uncg_0154D_10788.pdf> [retrieved on 20151116] *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU101724B1 (de) * 2020-04-02 2021-10-04 Inflamed Pharma Gmbh Wirkstoffe zur medizinischen Verwendung
WO2021198504A1 (fr) * 2020-04-02 2021-10-07 Inflamed Pharma Gmbh Principes actifs à usage médical
CN115697318A (zh) * 2020-04-02 2023-02-03 炎症药物有限责任公司 医用活性物质

Also Published As

Publication number Publication date
PH12014000275A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
AU2017202343B2 (en) Neosaxitoxin combination formulations for prolonged local anesthesia
JP6353577B2 (ja) 組み合わせ組成物
AU2023204000A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
JP2017533211A5 (fr)
WO2016053121A1 (fr) Formulation pharmaceutique antivirale pour le traitement de la fièvre dengue, du virus de la grippe et du vih/sida
BRPI0914086A2 (pt) uso de paracetamol e ibuprofeno na preparação de um medicamento para o tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa e método de tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
US20140148447A1 (en) Agent for prophylactic and therapeutic treatment of herpes infections
UA76254C2 (en) Use of desoxypeganine for treating clinical depression
RU2680804C1 (ru) Стабильное средство лечения болезней суставов
US10213444B2 (en) Composition and method for treating bipolar disorder
Tab et al. Anticoagulation Therapy see page 595
UA144734U (uk) Спосіб лікування вірусних інфекційних захворювань
WO2019186342A1 (fr) Sels de liquides ioniques de l&#39;acide 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(diméthylamino)éthyl)amino)-1-hydroxyéthyl)-1-isopropyl-5a,5b,8,8,11a-pentaméthyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadécahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-diméthyl-4-oxobutanoïque
Velotti et al. Anesthesia in Dentistry
CN110545809A (zh) 治疗发作性疾病的方法
EP1671639A1 (fr) Traitement de SIDA avec une therapiecombinée a base de sulphates de curdlane
van der Bijl Role of antivirals in influenza
RU2015148884A (ru) Эсликарбазепина ацетат и способы его применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15782087

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15782087

Country of ref document: EP

Kind code of ref document: A1